[Anticoagulation in patients with venous thromboembolism].
Deep venous thrombosis and pulmonary embolism are considered to be two variants of one disease--'venous thromboembolism'. Pathogenesis, therapy and prognosis of these both entities are very similar and therefore the term 'venous thromboembolism' has been used in recent literature. The cornerstone of therapy is anticoagulation and initially consists of heparin for at least five days. Because of pharmacokinetic advantages low molecular weight heparins are the therapy of choice. They are as efficient and save as unfractionated heparins and allow weight-adapted dosing with daily subcutaneous injections in most patients. Low molecular weight heparins do not require regularly laboratory monitoring with few exceptions, e.g. renal failure. Therefore outpatient treatment of deep venous thrombosis is possible in most patients. Although there are promising data about outpatient treatment of pulmonary embolism, this is still being studied and can not be recommended outside clinical trials. Introduction of coumarin therapy for venous thromboembolism should be started on day 1 of diagnosis, keeping the total duration of heparin therapy at no more than five days and therefore minimizing the incidence of heparin-induced thrombocytopenia. Evidence from multiple studies indicates that effective coumarin therapy in venous thromboembolism is usually reflected by an INR of 2.0 to 3.0. In patients with massive and hemodynamically relevant thromboembolism alternative therapeutic approaches such as thrombolytic therapy, thrombectomy or insertion of intravenous filters may be useful. Adequately fit compression stockings can reduce the risk of post-thrombotic syndrome after deep venous thrombosis.
Rüfer
A
A
Abteilung für Hämatologie, Medizinische Klinik, Kantonsspital Luzern.
Wuillemin
W A
WA
D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use*; D001458:Bandages; D002986:Clinical Trials as Topic; D003374:Coumarins / Q000008:administration & dosage / Q000627:therapeutic use*; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007279:Injections, Subcutaneous; D010045:Outpatients; D011655:Pulmonary Embolism / Q000188:drug therapy* / Q000601:surgery / Q000628:therapy; D017131:Thrombectomy; D013921:Thrombocytopenia / Q000139:chemically induced / Q000517:prevention & control; D015912:Thrombolytic Therapy; D013997:Time Factors; D016306:Vena Cava Filters; D020246:Venous Thrombosis / Q000188:drug therapy* / Q000601:surgery / Q000628:therapy
D000925:Anticoagulants; D003374:Coumarins; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D006493:Heparin; C030123:coumarin